With the FDA approval and imminent shipping of Mylan’s generic glatiramer acetate (GA 20mg and 40mg) injections, pricing pressure will increase on Teva’s Copaxone and Sandoz’s Glatopa, the first-to-market generic GA 20mg, and payer pressure can be expected to markedly expand.

Click the button below to view highlights from this report:

Download Report Spotlight